Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | STAT3 | P40763 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6882235 | 0.83 | LMNA (0.44) | LMNAPTPN1MEN1CYP3A4ALOX15 | |
| SCHEMBL3851126 | 0.83 | LMNA (0.44) | LMNAPTPN1MEN1CYP3A4ALOX15 | |
| SCHEMBL736990 | 0.83 | LMNA (0.44) | LMNAPTPN1MEN1CYP3A4ALOX15 | |
| SCHEMBL16796012 | 0.83 | LMNA (0.44) | LMNAPTPN1MEN1CYP3A4ALOX15 | |
| SCHEMBL5933973 | 0.83 | LMNA (0.44) | LMNAPTPN1MEN1CYP3A4ALOX15 | |
| SCHEMBL1704609 | 0.79 | LMNA (0.46) | LMNAPTPN1MEN1CYP3A4ALOX15 | |
| SCHEMBL6402023 | 0.79 | LMNA (0.46) | LMNAPTPN1MEN1CYP3A4ALOX15 | |
| SCHEMBL21913451 | 0.77 | LMNA (0.47) | LMNAPTPN1MEN1CYP3A4ALOX15 | |
| SCHEMBL24133233 | 0.76 | LMNA (0.39) | LMNAPTPN1 | |
| SCHEMBL16193512 | 0.76 | LMNA (0.43) | LMNAPTPN1MEN1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013034416-A1 | ANTIMICROBIAL METHOD AND COMPOSITION | UNILEVER N.V. (NL) | 2013-03-14 | — | — | WO | disclosed |